- Home
- TLSI
as 07-26-2024 4:00pm EST
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | WESTMINSTER |
| Market Cap: | 150.5M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 22.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.32 - $12.83 | Next Earning Date: | 08-15-2024 |
| Revenue: | $21,983,000 | Revenue Growth: | 68.96% |
| Revenue Growth (this year): | 59.16% | Revenue Growth (next year): | 50.28% |
Latest TriSalus Life Sciences Inc. News
TLSI Breaking Stock News: Dive into TLSI Ticker-Specific Updates for Smart Investing
Business Wire
25 days ago
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
Business Wire
a month ago
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
Business Wire
2 months ago
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
Business Wire
2 months ago
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
Business Wire
2 months ago
TriSalus Reports Q1 2024 Financial Results and Business Update
Business Wire
3 months ago
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
Business Wire
3 months ago
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
Business Wire
3 months ago
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
Compare TLSI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TLSI TriSalus Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.